Biopharmaceutical company Sinovac Biotech Ltd (NASDAQ:SVA) stated on Tuesday that it recorded a loss to common shareholders of USD7.4m ( USD0.07 per basic and diluted share) for the first quarter ended 31 March 2020.
This marks a dip in earnings when compared with net income to common shareholders of USD1.2m (USD0.01 per basic and diluted share) in the same period of the previous year.
Sales of USD15.4m were recorded for the first quarter of 2020, down 57.9% from sale of USD36.6m in the first quarter of 2019.
While operating expenses decreased, net income attributable to common shareholders was impacted by the decrease in sales.
R&D expenses of USD5.7m were reported in the first quarter of 2020, a rise versus R&D of USD4.5m in the prior year period, as it continued to invest in its product pipeline including sIPV and PPV, as well as the research and development of the COVID-19 vaccine.
Gilead Sciences swings to loss in Q2 2020
BD board announces common and preferred stock dividends for quarter
Novartis announces not-for-profit portfolio of medicines for symptomatic COVID-19 treatment
SIRION Biotech achieves 26% rise in revenues for H1 2020 despite COVID19 pandemic
GHP Specialty Care's Q2 2020 results affected by COVID-19 pandemic
Chr.Hansen Holding reports strong Q3 results amid COVID-19 pandemic
Central England Co-op outlines exciting vision for its future in special film
Cranfield to host one of the UKs largest online graduation events so far
Perrigo agrees to sell Rosemont Pharmaceuticals business to UK-based private equity firm
Ameren Illinois Launches New Relief Measures for Customers Impacted by COVID-19